On April 20, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported the poster presentation of additional immunogenicity data from the VB-C-03 clinical trial at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data build on results initially presented at the 10th International Congress on Innovative Approaches in Head & Neck Oncology (ICHNO) in March 2026, which demonstrated a confirmed objective response rate of 38.5% and strong immunogenicity signals. The current results support an even more robust immunogenicity, with now 11 evaluable patients, where all 10 patients (100%) in the 6 and 9 mg dose groups showed HPV16-specific vaccine-induced immune responses. The responses were both rapid and durable, with a demonstrated persistence into the last analyzed timepoint at the completed end-of-treatment.
"The consistency and strength of the T-cell responses we are observing across patients underscore that abi-suva has the makings of a best-in-class vaccine for HPV16-positive cancers. For patients with recurrent or metastatic head and neck cancer, where current treatments offer a response rate of only around 19%, a therapy that can generate this quality of immune response alongside meaningful clinical activity could represent a real step forward. We enter the Abili-T trial with a well-defined dose, a strong immune response profile, and a competitive data package that sets abi-suva apart from other approaches in this indication and we are deeply motivated by the opportunity to make a difference for these patients," said Agnete Fredriksen, CSO and Co-founder of Nykode Therapeutics.
The poster will be available after the session at the Company’s Webpage: View Source
(Press release, Nykode Therapeutics, APR 20, 2026, View Source [SID1234664545])